To compare estimated primary-prevention aspirin eligibility using PREVENT-ASCVD risk thresholds with eligibility based on the USPSTF’s PCE threshold of 10% or greater among US adults aged 40 to 59 years without prior ASCVD or selected major bleeding-risk characteristics.
Approach:
Design and data: Cross-sectional analysis of publicly available NHANES data from 2013–2020, using survey weights to produce nationally representative estimates.
Participants: Included 4,289 adults aged 40–59 years; excluded those with prior ASCVD or specified characteristics associated with major bleeding risk.
Risk comparison: Compared PCE eligibility at 10% or greater with PREVENT-ASCVD eligibility at thresholds of 5%, 7.5%, and 10% or greater.
Key Findings:
Overall estimated eligibility was 8.5% using PCE at 10% or greater, compared with 10.4%, 3.4%, and 1.1% using PREVENT thresholds of 5%, 7.5%, and 10%, respectively.
Among aspirin nonusers, PCE classified 7.4% as eligible; PREVENT at 5% classified 8.7%, the closest estimate to PCE.
Among PCE-eligible aspirin nonusers, 17.2% would no longer qualify at PREVENT 5%, 66.5% at 7.5%, and 89.9% at 10%.
Each PREVENT threshold also identified aspirin nonusers who were not eligible under the PCE criterion.
Interpretation:
In this analysis, PREVENT thresholds from 5% to 10% substantially changed estimated aspirin eligibility relative to the PCE threshold. A PREVENT threshold of 5% produced population-level eligibility estimates most similar to PCE at 10%; the study did not establish a PREVENT-specific threshold for aspirin discussions.
Limitations:
ASCVD history and aspirin use were self-reported, so some participants may have been misclassified.
Bleeding risk was assessed using pragmatic survey-based surrogates rather than a validated questionnaire item.
Excluding participants with bleeding-risk characteristics, some of which also increase cardiovascular risk, limits generalizability to people with both risks.
The analysis was cross-sectional and estimated eligibility; it did not evaluate aspirin treatment outcomes.
Conclusion:
The authors state that PREVENT-specific microsimulation studies evaluating thresholds between 5% and 10% are needed before recommendations can be formally revised for contemporary risk assessment.
Researchers demonstrate how transient modified mRNA therapy can stimulate heart muscle cell proliferation and improve cardiac function following myocardial infarction